MedTrace Logo

Clinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases

NCT07727083 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2026-07-27

No results posted yet for this study

Summary

This is a multicenter, non-interventional, ambidirectional cohort study of Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases. The study consists of a retrospective clinical cohort of 500 consecutively diagnosed patients with extranodal NK/T-cell lymphoma and a prospective clinical-biological cohort of 1,000 newly diagnosed patients with extranodal NK/T-cell lymphoma, aggressive NK-cell leukemia, systemic chronic active Epstein-Barr virus disease of T/NK-cell type, or Epstein-Barr virus-positive nodal T/NK-cell lymphoma.

The study will characterize clinical features, treatment pathways, response, relapse or progression patterns, and long-term survival. The prospective cohort will additionally undergo standardized collection of peripheral blood and optional tumor tissue specimens at predefined clinical time points. Clinical, molecular, viral, and immune biomarkers will be evaluated for their associations with treatment response, treatment failure, disease progression, and survival. No treatment is assigned by the study.

Conditions

  • Extranodal NK/T-cell Lymphoma
  • Aggressive NK-Cell Leukemia
  • Systemic Chronic Active Epstein-Barr Virus Disease
  • Epstein-Barr Virus-Positive Nodal T/NK-Cell Lymphoma
  • Epstein-Barr Virus-Positive T/NK-Cell Lymphoproliferative Disease

Sponsors & Collaborators

  • Rong Tao

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-25
Primary Completion
2035-12-31
Completion
2035-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07727083 on ClinicalTrials.gov